Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Howard I. Scher(Kantonsspital Baselland Standort Bruderholz), Charles L. Sawyers(Memorial Sloan Kettering Cancer Center), Martin Fleisher(Memorial Sloan Kettering Cancer Center), Steven M. Larson(Memorial Sloan Kettering Cancer Center), Michael J. Morris(The University of Texas Southwestern Medical Center), Mary‐Ellen Taplin(University of Massachusetts Chan Medical School), Daniel C. Danila, Tomasz M. Beer(Oregon Health & Science University), John L. Humm(Memorial Sloan Kettering Cancer Center), Lynn Seely, Joshi J. Alumkal(University of Michigan), Aseem Anand(Memorial Sloan Kettering Cancer Center), Mohammad Hirmand, Eleni Efstathiou(The University of Texas MD Anderson Cancer Center), Evan Y. Yu(University of Washington), David T. Hung, Celestia S. Higano(University of Washington), Julia Shelkey(Memorial Sloan Kettering Cancer Center), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center)
Cited by 1,082
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k